Prognostic Value of Concomitant Bronchiectasis in Newly Diagnosed Diffuse Panbronchiolitis Patients on a Maintenance Therapy with Macrolides

Table 1

Demographic, clinical, and laboratory findings of DPB subjects with and without bronchiectasis at baseline.


Parameter	Whole group ()	DPB with bronchiectasis ()	DPB without bronchiectasis ()	value^▲

Age (years)	52.5 ± 16.8	53.0 ± 16.6	51.9 ± 17.3	0.597
Female	91 (41.9)	59 (45.7)	32 (36.4)	0.108
BMI (kg/m²)	21.3 ± 5.3	19.7 ± 3.9	23.8 ± 6.2	<0.001
Smoking history	52 (24.0)	34 (26.4)	18 (20.5)	0.317
Disease duration (year)^※	7.0 (5.0, 9.0)	7.0 (5.0, 10.5)	6.5 (5.0, 9.0)	0.088
Disease history
Chronic sinusitis	197 (90.8)	116 (89.9)	81 (92.0)	0.596
Chronic bronchitis	19 (8.8)	14 (10.9)	5 (5.7)	0.186
Emphysema	11 (5.1)	7 (5.4)	4 (4.5)	0.771
Preexisting tuberculosis	24 (11.1)	17 (13.2)	7 (8.0)	0.228
Hypertension	42 (19.4)	23 (17.8)	19 (21.6)	0.491
Diabetes	10 (4.6)	6 (4.7)	4 (4.5)	0.971
Cardiovascular diseases	14 (6.5)	9 (7.0)	5 (5.7)	0.703
Rheumatic diseases	10 (4.6)	6 (4.7)	4 (4.5)	0.971
Pulmonary surgery history	9 (4.1)	7 (5.4)	2 (2.3)	0.253
Clinical manifestations
Cough	217 (100)	129 (100)	88 (100)	1.000
Sputum production	216 (99.5)	129 (100)	87 (98.9)	1.000
Shortness of breath	166 (76.5)	112 (86.82)	54 (61.4)	<0.001
Exertional dyspnea	194 (89.4)	118 (91.5)	76 (86.4)	0.230
Hemoptysis	50 (23.0)	36 (27.9)	14 (15.9)	0.039
Body weight loss	33 (15.2)	25 (19.4)	8 (9.1)	0.038
Crackle	119 (54.8)	72 (55.8)	47 (53.4)	0.727
Wheezing	53 (24.4)	30 (23.3)	23 (26.1)	0.628
Laboratory findings
pH	7.41 (7.39, 7.43)	7.41 (7.39, 7.43)	7.41(7.39, 7.43)	0.674
P_aCO₂ (mmHg)	40.7 (37.2, 45.3)	40.8 (37.1, 45.6)	40.5 (38.0, 44.7)	0.865
P_aO₂ (mmHg)	80.0 ± 15.7	78.2 ± 14.7	82.7 ± 16.8	0.037
WBC (10 × 9/L)	7.6 ± 2.7	7.3 ± 2.6	7.9 ± 2.7	0.143
Neutrophil (%)	63.3 ± 11.7	64.3 ± 11.4	61.9 ± 11.9	0.134
CRP (mg/L)	4.8 (1.6, 12.4)	4.6 (1.6, 15.0)	5.5 (1.5, 11.7)	0.687
ESR (mm/h)	20.2 (9.2, 36.7)	19.6 (8.0, 35.4)	20.4 (10.3, 37.4)	0.522
Positive CHA test^■	49 (22.6)	30 (23.3)	19 (21.6)	0.773
Pulmonary function tests
FVC (% pred)	74.8 ± 20.6	72.6 ± 20.9	78.0 ± 19.9	0.058
FEV₁ (% pred)	60.7 ± 15.4	58.9 ± 14.1	63.3 ± 16.8	0.040
FEV₁/FVC	65.0 ± 8.1	64.1 ± 7.4	66.2 ± 8.9	0.070
FEF75 (% pred)	39.8 (32.6, 55.9)	38.2 (34.1, 54.5)	41.4 (29.3, 57.5)	0.712
RV (% pred)	149.4 (123.3, 178.5)	152.6 (125.8, 181.6	145.6 (121.3, 171.0	0.213
Microorganisms
Pseudomonas aeruginosa	77 (35.5)	58 (45.0)	19 (21.6)	<0.001
Haemophilus influenzae	34 (15.7)	22 (17.1)	12 (13.6)	0.496
Nontuberculous mycobacterium	8 (3.7)	5 (3.9)	3 (3.4)	1.000
Streptococcus viridans	3 (1.4)	3 (2.3)	0 (0)	0.273
Candida albicans	19 (8.8)	8 (6.2)	11 (12.5)	0.107
Acinetobacter baumannii	5 (2.3)	5 (3.9)	0 (0)	0.082
Neisseria bacteria	16 (7.4)	6 (4.7)	10 (11.4)	0.063
Klebsiella pneumoniae	2 (0.9)	2 (1.6)	0 (0)	0.516
Enterobacter cloacae	4 (1.8)	2 (1.6)	2 (2.3)	1.000

Data are presented as mean ± standard deviation, median (interquartile range), or numbers (percentages). BMI: body mass index; CHA: cold hemagglutination; CI: confidence interval; CRP : C-reactive protein; DPB: diffuse panbronchiolitis; ESR: erythrocyte sedimentation rate; FEF: forced expiratory flow; FEV₁: forced expiratory volume in 1 second; FVC: forced vital capacity; OR: odds ration; P_aCO₂: arterial pressure of carbon dioxide; P_aO₂: arterial pressure of oxygen; pH: potential of hydrogen; RV: residual volume; WBC: white blood cell. ^※Disease duration was defined as the time from the first DPB symptoms onset to the first visit to hospital. ^▲Comparison of DPB subjects with and without bronchiectasis. ^■A positive CHA test was defined as a value greater than 1 : 64.

Canadian Respiratory Journal

Prognostic Value of Concomitant Bronchiectasis in Newly Diagnosed Diffuse Panbronchiolitis Patients on a Maintenance Therapy with Macrolides

Table 1